Author’s response to reviews

Title: Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study

Authors:

Hitomi Hara (mitohi@med.kobe-u.ac.jp)
Teruya Kawamoto (trykwmt@med.kobe-u.ac.jp)
Naomasa Fukase (nfukase@msn.com)
Yohei Kawakami (yohei_kawakami@hotmail.com)
Toshiyuki Takemori (westlife_take@yahoo.co.jp)
Shuichi Fujiwara (fujiwarashuuichi@yahoo.co.jp)
Kazumichi Kitayama (kazoo_728@yahoo.co.jp)
Kotaro Nishida (kotaro@med.kobe-u.ac.jp)
Ryosuke Kuroda (kurodar@med.kobe-u.ac.jp)
Toshihiro Akisue (akisue@med.kobe-u.ac.jp)

Version: 2 Date: 14 Jun 2019

Author’s response to reviews:

Dear reviewers and editors

Enclosed please find a manuscript entitled "Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study ".

We thank referees for careful reading our manuscript and for your acceptance.
We agree and understand that this study protocol would be limited, so we will leave the study of each different sarcomas to the future research. We have revised our manuscript. We look forward to publication of our manuscript in BMC Cancer. Thank you very much.

Sincerely yours,

Hitomi Hara, MD

Department of Orthopaedic Surgery, Kobe University Graduate of Medicine,
7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
Tel: +81-78-382-5985, Fax: +81-78-351-6944
e-mail: mitohi@med.kobe-u.ac.jp

Editor Comments:
The comments of Reviewer 2 need to be addressed by a thorough discussion of the limitations within the manuscript.

Reviewer reports:
Scott Okuno (Reviewer 1): The modifications/edits have improved the submitted manuscript.

As noted prior, this regimen has been studies and published by many investigators but not in Japan. However, the study combines both bone and soft tissue that results would be limited applicability.
Sandro Pasquali (Reviewer 2): Although the text has been improved, the limitations of the study protocol have not been improved. Comments of both reviewers have been addressed without resulting in modification of the study protocol. This is of great importance as Authors are seeking approval for the drug combination in Japan. Compromising the study design will not allow this study to reach its target.

Thank you for your valuable suggestion. We understand the limitation of this study, so we will evaluate the result and intend to plan the future study. (Page 11, line221-227)